Morgans AK - Search Results

1

Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses.

Hu JR, Duncan MS, Morgans AK, Brown JD, Meijers WC, Freiberg MS, Salem JE, Beckman JA, Moslehi JJ. Hu JR, et al. Among authors: morgans ak. Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):e55-e64. doi: 10.1161/ATVBAHA.119.313046. Epub 2020 Jan 23. Arterioscler Thromb Vasc Biol. 2020. PMID: 31969015 Free PMC article. Review.

2

Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy.

Morgans AK, Smith MR, O'Malley AJ, Keating NL. Morgans AK, et al. Cancer. 2013 Feb 15;119(4):863-70. doi: 10.1002/cncr.27830. Epub 2012 Oct 12. Cancer. 2013. PMID: 23065626 Free PMC article.

3

Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy.

Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Resnick MJ, Barocas DA, Penson DF. Morgans AK, et al. J Urol. 2015 Apr;193(4):1226-31. doi: 10.1016/j.juro.2014.11.006. Epub 2014 Nov 11. J Urol. 2015. PMID: 25451829 Free PMC article.

4

Cardiology Patient Page. ABCDE Steps for Heart and Vascular Wellness Following a Prostate Cancer Diagnosis.

Guan J, Khambhati J, Jones LW, Morgans A, Allaf M, Penson DF, Moslehi J. Guan J, et al. Circulation. 2015 Nov 3;132(18):e218-20. doi: 10.1161/CIRCULATIONAHA.115.012521. Circulation. 2015. PMID: 26527696 Free PMC article. No abstract available.

5

Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer.

Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, Moslehi J. Bhatia N, et al. Among authors: morgans ak. Circulation. 2016 Feb 2;133(5):537-41. doi: 10.1161/CIRCULATIONAHA.115.012519. Circulation. 2016. PMID: 26831435 Free PMC article. Review. No abstract available.

6

Emerging Therapies in Metastatic Prostate Cancer.

Sonnenburg DW, Morgans AK. Sonnenburg DW, et al. Among authors: morgans ak. Curr Oncol Rep. 2018 Apr 11;20(6):46. doi: 10.1007/s11912-018-0692-z. Curr Oncol Rep. 2018. PMID: 29644451 Review.

7

Adjuvant therapy in high-risk prostate cancer.

Shevach J, Chaudhuri P, Morgans AK. Shevach J, et al. Among authors: morgans ak. Clin Adv Hematol Oncol. 2019 Jan;17(1):45-53. Clin Adv Hematol Oncol. 2019. PMID: 30843898 Review.

8

Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.

Weiner AB, Nettey OS, Morgans AK. Weiner AB, et al. Among authors: morgans ak. Curr Treat Options Oncol. 2019 Jul 9;20(9):69. doi: 10.1007/s11864-019-0668-8. Curr Treat Options Oncol. 2019. PMID: 31286275 Review.

9

Quality of Life-Focused Decision-Making for Prostate Cancer.

Shevach J, Weiner A, Morgans AK. Shevach J, et al. Among authors: morgans ak. Curr Urol Rep. 2019 Aug 29;20(10):57. doi: 10.1007/s11934-019-0924-2. Curr Urol Rep. 2019. PMID: 31468212 Review.

10

Genetically-informed treatment for advanced and metastatic prostate cancer.

Morgans AK, Szymaniak BM. Morgans AK, et al. Can J Urol. 2019 Oct;26(5 Suppl 2):54-56. Can J Urol. 2019. PMID: 31629435 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

171 results

Search Page